Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>FY05/24 revenue was JPY3.3bn, operating profit JPY1.0bn, recurring profit JPY1.1bn, and net income JPY749mn, all down YoY.</li><li>Enjin's FY05/25 forecast: revenue JPY2.7bn, operating profit JPY548mn, recurring profit JPY548mn, and net income JPY380mn, all expected to decline YoY.</li><li>Enjin revised its medium-term business plan due to HR challenges and plans to release updated targets reflecting the current environment.</li></ul>

FY05/24 revenue was JPY3.3bn, operating profit JPY1.0bn, recurring profit JPY1.1bn, and net income JPY749mn, all down YoY.Enjin's FY05/25 forecast: revenue JPY2.7bn, operating profit JPY548mn, recurring profit JPY548mn, and net income JPY380mn, all expected to decline YoY.Enjin revised its medium-term business plan due to HR challenges and plans to release updated targets reflecting the current environment.

Enjin (7370 JP): Full-year FY05/24 flash update

Japan/Asia Long-Short, LightStream Research

Mio Kato

Japan/Asia Long-Short

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

<p>Enjin is aiming to disrupt the public relations business in Japan by offering standardised services to SMEs and even a DIY direct matching service being media and corporates looking for PR. Growth rates have been attractive and we lean positive but there are some governance niggles to be aware of.</p>

Enjin is aiming to disrupt the public relations business in Japan by offering standardised services to SMEs and even a DIY direct matching service being media and corporates looking for PR. Growth rates have been attractive and we lean positive but there are some governance niggles to be aware of.

Enjin IPO – Small Public Relations Disruptor with Strong Growth

Japan

Softmax Co., Ltd. provides medical information services including electronic medical record system and associated support.

KAINOS Laboratories, Inc. manufactures and sells clinical reagents.  The Company specializes in biochemical reagents as well as immune serum studies.  Kainos Laboratories produces in-house products including measuring equipment and tools through focus on research and development.  The Company also has a close relation with Hitachi Chemical Company for technological tie-up.

MEDRx Co Ltd., is a pharmaceutical company. The Company develops medicines for the pharmaceutical industry based on drug formulation technologies required for Drug Delivery Systems.

Immuno-Biological Laboratories Co., Ltd. specializes in research and development of antibodies.  The Company sells antibody related assays and medicinal drugs to research institutions and pharmaceutical companies.

Precision System Science Co., Ltd. manufactures tools, equipment, and software for gene, immunity, bacteria, and medicine research and analysis.  The Company develops DNA sampling system, illuminant capture operation system, and bacteria tests with use of magtration technology (magnetic particles used for reactions, sampling, irradiation, and measuring.)

Gene Techno Science Co., Ltd. is a biomedicine company that researches and developes drugs. In addition to drug development, the company also supply the pharmaceutical ingredients.

COSMO BIO Co Ltd exports, imports, sells research reagents, instruments, and diagnostics mainly to laboratories and testing organizations. The Company also provides a variety of products and technical information through catalogues, newsletters, leaflets, internet, and seminars.

KAWAMOTO CORPORATION manufactures medical and nursing products including gauze, bandages, and absorbent cotton.  The Company also produces antibacterial wet paper towels, sanitary products, and childcare goods.

UCHIYAMA HOLDINGS Co., Ltd. is a holding company manages health care service, Karaoke shops and restaurants.

Nippon Chemiphar Co., Ltd. produces and sells medicine for medical use.  The Company also produces medical, health, and cosmetics products.  Nippon Chemiphar sterilizes medical instruments for hospitals and operates nursing home for elderly.

Established in May 2001, Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a leading company dedicated to safeguarding the well-being of mother and child. The Group is listed on the Mainboard of the Singapore Exchange since 2012 and is a pioneer in private cord blood banking in Asia.

Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets, namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, Hong Kong, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks and it is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife has also established its presence in Myanmar, Vietnam, Macau, Brunei and Bangladesh.

Beyond cord blood, cord lining and cord tissue banking, Cordlife offers a comprehensive suite of diagnostics services for the family including non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening and family genetic screening services.  Quality and customer focus are amongst some of the cornerstones of Cordlife.

Cynata Therapeutics Ltd is involved in regenerative medicine.  The Company is focused on the commercialization of a stem cell platform.

Orientbio Inc. provides laboratory animals and equipment for medical experiment.  The Company also specializes in manufacturing wrist watches and components such as cases, bracelets, and dials.

Nova Eye Medical Limited manufactures and develops medical technology devices. The Company develops a suite of glaucoma treatment technologies that enable ophthalmologists to treat across the full spectrum of the glaucoma disease process. Nova Eye Medical serves customers worldwide.

Genematrix Inc. provides diagnostics & therapeutic solution.  The Company's services are based on Restriction Fragment Mass Polymorphism (RFMP) technology and applied to theranostics, prognosis, and molecular diagnosis.

Cutera, Inc. develops and manufactures aesthetic laser systems.  The Company markets the CoolGlide family of products for removal of unwanted hair and treatment of vascular lesions.  Cutera markets the systems to dermatologists, plastic surgeons, and other practitioners worldwide.

IDT Australia Limited is engaged in the development and manufacture of pharmaceutical products, both in active pharmaceutical ingredient and finished dose forms. The Company also provides research and development, clinical trial, and other technical services supporting the pharmaceutical and biotech industries.

China Regenerative Medicine International Limited is engaged in research and development of bio-medical and healthcare products, and medical techniques, the provision of the production and sales of tissue engineering products and its related by-products, as well as sales and distribution of medical products and equipment.

Cryosite Limited provides biological storage and sample management services to the medical industry in Australia and New Zealand.  Services include the collection, processing and storage of cord blood stem cells for private use, storage of biological material for biological based industries and storage and distribution of temperature-critical products like drugs and micro-organisms.

General Biologicals Corp. produces molecular diagnostic product. The Company's also offer research development, marketing and servicing of products and solutions for hospitals, medical laboratory and blood bank, and research and industry.

Enjin Co., Ltd. offers commercial services. The Company provides corporations and managers public relations supporting, medical institutions and doctors public relations supporting, platform services, and other services. Enjin provides its services throughout Japan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Enjin (7370 JP)

Enjin (7370 JP): Full-year FY05/24 flash update

FY05/24 revenue was JPY3.3bn, operating profit JPY1.0bn, recurring profit JPY1.1bn, and net income JPY749mn, all down YoY. Enjin's FY05/25...

Shared Research

Enjin IPO – Small Public Relations Disruptor with Strong Growth

PR service disruptor Enjin's growth rates have been attractive and we lean positive on its IPO but there are some governance niggles to be aware of.

Mio Kato

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)